keep an eye on VICL, they are about to release P3 results for their drug, a competitor of ONCS drug. I think it will fail. If it does, it should make ONCS spike up (less competition). And if it passes, it shouldn't hurt ONCS much, because from what i read, ONCS has a much better response rate that VICL's A-7 drug. Will be interesting to see how it plays out. All imo, do your own dd
The company has both data for MCC and metastic melanoma in the near future. The company's OMS electroporation system has shown no negative effects to date. In my opinion, the MCC study is most important. There is no treatment for MCC. It is an Orphan indication. A success in treating the disease could take the stock significantly higher. Because of its market cap, there really is no risk, but loads of upside.